Deal satisfies Janssen HBV strategy, validates Arrowhead platform

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) granted Janssen Pharmaceuticals Inc. rights to an HBV candidate for its curative combination toolbox. The deal, worth up to $3.7 billion, is Arrowhead's first billion dollar deal for a platform that became its focal point following a 2016 toxicology setback.

The Johnson & Johnson (NYSE:JNJ) unit gains exclusive, worldwide rights to ARO-HBV and options to exclusively license up to three candidates identified against undisclosed, Janssen-selected targets using Arrowhead's Targeted RNAi Molecule (TRiM) platform...